I would be grateful if you could send me two datasets and provide answers to the questions in section 3 for your Trust, to inform this analysis:
(1) Drug Patient Level Contract Monitoring (DrPLCM) report
Data fields from the DrPLCM report, as specified in table 1 (below). Please do not send patient IDs or cost data, as I appreciate this would compromise data privacy and commercial sensitivity.
(2) SACT Cancer report
An extract from the chemotherapy ePMA system showing patients treated by drug and diagnosis, as specified in table 2 (below). Please also address the questions in section 3 which aims to give me top level information on the number of patients treated for different types of breast cancer.
Please email your response by reply with the data in .csv format for the two datasets and input your responses for section 3 in the respective boxes. Feel welcome to contact me if you have any questions about this request.
(1) Table 1 - Drug Patient Level Contract Monitoring (DrPLCM) report
Please select all DrPLCM records between Apr 2022 and Aug 2022 for all hospitals in your NHS Trust.
|
Name of “Data Element” from NHS Data Model and Dictionary for DrPLCM
|
|
FINANCIAL MONTH
|
|
FINANCIAL YEAR
|
|
ORGANISATION IDENTIFIER (CODE OF PROVIDER)
|
|
ORGANISATION IDENTIFIER (CODE OF COMMISSIONER)
|
|
ORGANISATION SITE IDENTIFIER (OF TREATMENT)
|
|
ACTIVITY TREATMENT FUNCTION CODE
|
|
CLINICAL INTERVENTION DATE (DRUG DISPENSED)
|
|
THERAPEUTIC INDICATION CODE (SNOMED CT, OR ICD-10, OR TEXT DESCRIPTION)
|
|
HIGH-COST TARIFF EXCLUDED DRUG CODE (SNOMED CT DM+D)
|
|
DM+D TAXONOMY CODE (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
DRUG NAME (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
ROUTE OF ADMINISTRATION (SNOMED CT DM+D)
|
|
DRUG STRENGTH (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
DRUG VOLUME (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
DRUG PACK SIZE (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
DRUG QUANTITY OR WEIGHT PROPORTION (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
UNIT OF MEASUREMENT (SNOMED CT DM+D)
|
|
DISPENSING ROUTE (HIGH-COST TARIFF EXCLUDED DRUG)
|
|
COMMISSIONED SERVICE CATEGORY CODE
|
|
PROVIDER REFERENCE NUMBER
|
|
SPECIALISED SERVICE CODE
|
|
NATIONAL CANCER DRUGS FORM CODE
|
|
CONTRACT MONITORING ADDITIONAL DETAIL (FIRST)
|
|
CONTRACT MONITORING ADDITIONAL DESCRIPTION (FIRST)
|
(2) Table 2 - SACT Cancer report
Please select data records from the chemotherapy ePMA system between Apr 2022 and Aug 2022, for all solid tumour or haematological malignancies (ICD-10 primary diagnosis codes = C* or D*).
|
Data Field from NHS Data Model and Dictionary for SACT
|
|
ORGANISATION IDENTIFIER (CODE OF PROVIDER)
|
|
ORGANISATION IDENTIFIER (OF SACT THERAPY ADMINISTRATION)
|
|
PRIMARY DIAGNOSIS (tumour type)
|
|
PRIMARY DIAGNOSIS CODE (SNOMED CT OR ICD-10 3 or 4 digit)
|
|
MORPHOLOGY ICD-O
|
|
DIAGNOSIS CODE (SNOMED CT)
|
|
ADJUNCTIVE THERAPY TYPE
|
|
SACT DRUG NAME
|
|
SACT DRUG (SNOMED CT DM+D)
|
|
SACT ACTUAL DOSE
|
|
SACT UNIT OF MEASUREMENT
|
|
SACT THERAPY ADMINISTRATION DATE
|
|
SACT DRUG TREATMENT INTENT
|
|
CLINICAL TRIAL INDICATOR
|
|
TNM STAGE
|
|
DRUG REGIMEN DESCRIPTION
|
|
NUMBER OF PLANNED CYCLES
|
|
NUMBER OF PATIENT RECORDS
|
(3) Breast Cancer information
I am interested to know the total number of patients with breast cancer treated with medicines between Apr 2022 and Aug 2022. When responding to the questions below please count all patients treated with chemotherapies, biological agents, hormonal therapies etc., but exclude patients treated with surgery only and/or radiotherapy only.
|
1. How many patients with breast cancer were treated in total?
|
|
|
|
2. How many patients with breast cancer were treated at the following stages?
|
|
|
-
- Early breast cancer (stages I or II)
|
|
|
-
- Locally advanced breast cancer (stage III)
|
|
|
-
- Metastatic breast cancer (stage IV)
|
|
|
|
3. How many patients with breast cancer were treated in the following categories of tumour characteristics and staging?
|
|
|
Neoadjuvant
|
HR+ve (ER+ve &/or PR+ve)
|
|
|
|
|
Adjuvant
|
HR+ve (ER+ve &/or PR+ve)
|
|
|
|
|
Neoadjuvant
|
HR+ve, HER2+ve
|
|
|
|
|
Adjuvant
|
HR+ve, HER2+ve
|
|
|
|
|
Neoadjuvant
|
HR+ve, HER2-ve
|
|
|
|
|
Adjuvant
|
HR+ve, HER2-ve
|
|
|
|
|
Neoadjuvant
|
HR+ve, HER2-ve, node positive
|
|
|
|
|
Adjuvant
|
HR+ve, HER2-ve, node positive
|
|
|
|
|
Neoadjuvant
|
HER2+ve, node positive
|
|
|
|
|
Adjuvant
|
HER2+ve, node positive
|
|
|
|
|
Neoadjuvant
|
BRCA1/2 germline mutation positive
|
|
|
|
|
Adjuvant
|
BRCA1/2 germline mutation positive
|
|
|
|
|
Neoadjuvant
|
Triple negative
|
|
|
|
|
Adjuvant
|
Triple negative
|
|
|
|
|
All
|
PIK3CA mutation
|
|
|
|
|
All
|
HR+ve (ER+ve &/or PR+ve)
|
|
|
|
|
All
|
HER2+ve
|
|
|
|
|
All
|
HR+ve, HER2-ve
|
|
|
|
|
All
|
BRCA1/2 germline mutation positive
|
|
|
|
|
All
|
Triple negative, PD-L1 positive
|
|
|
|
|
All
|
Triple negative, PD-L1 negative
|
|
|
|
|
All
|
PIK3CA mutation
|
|
|
|
|
All
|
HR+ve (ER+ve &/or PR+ve)
|
|
|
|
|
All
|
HER2+ve
|
|
|
|
|
All
|
HR+ve, HER2-ve
|
|
|
|
|
All
|
BRCA1/2 germline mutation positive
|
|
|
|
|
All
|
Triple negative, PD-L1 positive
|
|
|
|
|
All
|
Triple negative, PD-L1 negative
|
|
|
|
|
All
|
PIK3CA mutation
|
|
|
Definitions
HER2 = human epidermal growth factor 2 protein;
HR+ve = hormone receptor positive (oestrogen receptor positive, ER+ve, progesterone receptor positive, PR+ve, or both ER+ve and PR+ve);
Triple negative = HER2-ve and HR-ve (ER-ve and PR-ve)
BRCA = breast cancer gene;
PD-L1 = programmed death-1 ligand;
PIK3CA = Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha
